Skip to main content

Table 2 Studies assessing HRQL in Hodgkin lymphoma patients (N = 65)

From: Health-related quality of life in Hodgkin lymphoma: a systematic review

Primary Author Year Design Study Type Timepoints (as reported) N (HL Specific) Age (HL specific) Tx Status Measures Domains Assessed Quality Score
Fobair P [26] 1986 Cohort Cross-sectional Median 9 years post treatment 403 36.3 mean Off CES-D, Study-specific questionnaire Domain, Symptom 6
Kornblith AB [22] 1990 Cohort Cross-sectional 6.3 years mean post treatment 273 37 mean Off PAIS-SR, BSI, POMS, IES, Global Sexual Satisfaction Index Domain 5
Chao NJ [37] 1992 Cohort Longitudinal <1 year post treatment 24 N/S Off Study-specific questionnaire MultiD 2
Kornblith AB [23] 1992 Cohort Cross-sectional Mean 6.3 years post treatment 273 37 mean Off PAIS-SR, BSI, POMS, Global Sexual Satisfaction Index Domain 6
Kornblith [48] AB 1992 Cohort Cross-sectional Mean 2.2 years post treatment 93 35 median Off PAIS-SR, BSI, POMS, IES Domain 4
Bloom JR [49] 1993 Comparator: Cohort Cross-sectional 1 or more years post treatment 85 32.3 mean Off POMS, CES-D, Social Activity Scale Domain 6
van Tulder MW [30] 1994 Comparator: Cohort Cross-sectional Mean 14 years since diagnosis 81 43.6 mean Off SF-36, Maudsley Martital Questionnaire MultiD, Other 6
Joly F [38] 1996 Comparator: Case Control Cross-sectional Mean 10 years since diagnosis 93 42 mean Off EORTC QLQ-C30, Study-specific questionnaire MultiD, Other 6
Norum J [50] 1996 Cohort Cross-sectional Median 48 months since diagnosis 42 38 median Off IES, VAS Domain, Other 4
Norum J [51] 1996 Cohort Cross-sectional Median 48 months since diagnosis 42 38 median Off EuroQol MultiD 4
Norum J [52] 1996 Cohort Cross-sectional Median 48 months since diagnosis 42 38 median Off EORTC QLQ-C30 MultiD 3
Abrahamsen AF [29] 1998 Cohort Cross-sectional Mean 12 years since diagnosis 459 44 median Off Study-specific questionnaire Domain 6
Kornblith AB [24] 1998 Comparator: Cohort Cross-sectional Mean 5.9 years post treatment 273 37 median Off PAIS-SR, BSI, POMS, IES Domain 6
Greil R [13] 1999 Cohort Cross-sectional Mean 10.5 years since diagnosis 126 36.9 mean Off EORTC QLQ-C30 MultiD 6
Kaasa S [53] 1999 Comparator: Cohort Cross-sectional 3–20 years post treatment 459 44 mean Off SF-36, FQ MultiD, Symptoms 5
Loge JH [54] 1999 Cohort Cross-sectional Mean 12.2 years since diagnosis 459 44 mean Off HADS, FQ Domain, Symptom 6
Loge JH [55] 1999 Cohort Cross-sectional Mean 12.2 years since diagnosis 459 44 mean Off SF-36 MultiD 6
Van Schaik CS [56] 1999 Cohort Cross-sectional Median 21.9 years since diagnosis 33 21.9 median Off HUI2, HUI3 MultiD 3
Loge JH [32] 2000 Cohort Cross-sectional 3–23 years post treatment 421 19–74 years Off FQ, HADS, Study-specific questionnaire Domain. Symptom 6
Barr RD [57] 2001 Comparator: Cohort Cross-sectional Completed treatment at least 2 years prior 19 N/S Off HUI MultiD 2
Cameron CL [58] 2001 Cohort Cross-sectional Median 7 years since diagnosis 272 37 mean Off PAIS-SR, Symptom Report Domain, Symptom 4
Knobel H [35] 2001 Cohort Cross-sectional Mean 9 years since diagnosis 92 37 mean Off FQ Symptom 6
Zabora J [59] 2001 Cohort Cross-sectional 58 % diagnosed within 90 days from study 135 N/S Both BSI Domain 3
Zebrack BJ [43] 2002 Comparator: Cohort Cross-sectional Mean 16.2 years since diagnosis 1843 30.8 mean Off BSI Domain 5
Ganz PA [10] 2003 Comparator: RCT Longitudinal Trial registration (since diagnosis) 244 31.4 STLI, 33.7 CMT median Both SF-36, CARES-SF, SDS MultiD, Symptom 4
Gil-Fernández JJ [27] 2003 Cohort Cross-sectional Median 7.6 years since diagnosis 46 43 mean Off EORTC QLQ-C30, HADS MultiD, Other 5
Oldervoll LM [36] 2003 Cohort Longitudinal Mean post treatment: 6.6 years fatigued patients; 4.9 years non-fatigued patients 53 41 fatigue, 40 non-fatigued mean Off SF-36, FQ MultiD, Symptom 5
Rüffer JU [33] 2003 Comparator: Case Control Cross-sectional Median 5.2 years since diagnosis 818 31 median Off EORTC QLQ-C30, MFI, Life Situation Questionnaire MultiD, Symptom 5
Wettergren L [60] 2003 Cohort Cross-sectional Mean 14 years since diagnosis 121 47 mean Off SEIQol-DW MultiD 5
Adams MJ [16] 2004 Cohort Cross-sectional Median 14.3 years since diagnosis 48 31.9 median Off SF-36, Study-specific questionnaire MultiD 4
Wettergren L [28] 2004 Cohort Cross-sectional Mean 13 years since diagnosis 121 47 median Off SF-12, SEIQoL-DW, HADS MultiD, Domain 6
Hjermstad MJ [61] 2005 Cohort Cross-sectional Median 16.3 years since diagnosis 496 46 median Off FQ Symptom 6
Ng AK [34] 2005 Comparator: Cohort Cross-sectional Median 15 years since diagnosis 511 44 median Off FACIT-Fatigue Symptom 6
Wettergren L [62] 2005 Cohort Cross-sectional Median 14 years since diagnosis 121 NS Off SF-12, SEIQoL-DW MultiD 2
Hjermstad MJ [63] 2006 Cohort Cross-sectional Median 16.3 years since diagnosis 479 46 mean Off SF-36, FQ MultiD, Symptom 5
Mols F [21] 2006 Cohort Cross-sectional 5–15 years since diagnosis 132 NS Off SF-36, QoL-CS MultiD 6
Absolom K [64] 2007 Cohort Cross-sectional 15.7 years mean since diagnosis 50 39.7 mean Off SF-12, HADS MultiD, Domain 5
Aksnes LH [65] 2007 Comparator: Cohort Cross-sectional Mean since diagnosis: 14 years for males, 11 years for females 89 35 mean Off SF-36, HADS, FQ MultiD, Domain, Symptom 4
Oldervoll LM [66] 2007 Cohort Cross-sectional Mean 17 years since diagnosis 476 46 mean Off FQ Symptom 5
Goodman KA [19] 2008 Cohort Cross-sectional Median 12 years post treatment 60 43 median Off EORTC QLQ-C30 MultiD 6
Mulrooney DA [67] 2008 Comparator: Cohort Cross-sectional At least 15 years since diagnosis 995 NS Off FACIT-Fatigue, Pittsburgh Slee Quality Index, Epworth Sleepiness Scale Symptoms 4
Shimoda S [68] 2008 Cohort Cross-sectional Mean 16.5 years since diagnosis 15 NS Off HUI3 MultiD 2
Kiserud CE [14] 2009 Cohort Cross-sectional Mean 15.2 follow up years 138 45.7 mean Off BSFI, Fatigue questionnaire, HADS, SF-36 MultiD, Symptom, Domain 6
Heutte N [11] 2009 Comparator: RCT Longitudinal Mean 7.5 years since diagnosis 935 31 median Off EORTC QLQ-C30, MFI, Sexual Function Scale MultiD, Symptoms 6
Brandt J [69] 2010 Cohort Cross-sectional Median since diagnosis: HDCT 11 years, conventional chemotherapy 3.5 years 98 46 HDCT, 41 conventional median Off EORTC QLQ-C30, EQ-5D MultiD 6
Klaassen RJ [40] 2010 Cohort Longitudinal 2 weeks after first course of chemotherapy 49 14.7 mean Both PedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance Score MultiD, Other 4
Klaassen RJ [41] 2010 Comparator: Cohort Longitudinal 2 weeks after first course of chemotherapy 49 14.7 mean Both PedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance Score MultiD, Other 2
Miltényi Z [17] 2010 Cohort Cross-sectional Mean 9.8 years since diagnosis 168 43.11 median Off EORTC QLQ-C30 MultiD 6
Baptista RLR [70] 2012 Cohort Cross-sectional Median 7 years since diagnosis 200 29 median Off MFI Symptom 4
Khimani N [18] 2013 Cohort Longitudinal Median 24 years since diagnosis 273 52 median Off SF-36, FACIT-Fatigue MultiD, Symptom 5
Minn AY [20] 2012 Cohort Cross-sectional Median 10.2 years post treatment 71 26 median Off EORTC QLQ-C30 MultiD 5
Behringer K [12] 2013 Comparator: RCT Longitudinal At diagnosis 3208 36.4 mean Both EORTC QLQ-C30, MFI, Sexual Health Scale MultiD, Symptoms 6
Greaves P [39] 2014 Comparator: Cohort Cross-sectional Mean 20.3 years since diagnosis 280 53.1 mean Off FACT-BMT, IOC, Study-specific questionnaire MultiD, Other 5
Hamre H [44] 2013 Comparator: Cohort Cross-sectional Median 21.5 years since diagnosis 68 35 median Off FQ Symptom 5
Kim S [71] 2014 Cohort Cross-sectional Mean 6.7 years since diagnosis 58 43.3 mean Off EORTC QLQ-C30, HADS MultiD, Domain 6
Roper K [72] 2013 Cohort Longitudinal At completion of planned therapy 40 30.9 mean Off SF-12, HADS, SDS, IOC MultiD, Domain, Other 4
Soares A [45] 2013 Cohort Cross-sectional Median 7 years since diagnosis 200 29 median Off SF-12, QOL-CS, MOS-SSS, MFI MultiD, Symptom 4
Vissers PAJ [15] 2013 Cohort Cross-sectional Mean 5 years since diagnosis 150 47 mean Off EORTC QLQ-C30 MultiD 6
Calaminus G [46] 2014 Cohort Cross-sectional Mean 15.3 years since diagnosis 725 28.44 mean Off EORTC QLQ-C30 MultiD 6
Daniels LA [31] 2014 Cohort Cross-sectional Mean 4.6 years since diagnosis 180 46 mean Off EORTC QLQ-C30, Fatigue Assessment Scale, Study-specific questionnaire MultiD, Symtom, Domain 6
Daniels LA [73] 2014 Cohort Longitudinal Mean 21 years since diagnosis 43 47 mean Off EORTC QLQ-C30, Fatigue Assessment Scale, HADS MultiD, Domain, Symptom 4
Oerlemans S [25] 2014 Comparator: Case Control Longitudinal Mean 4.7 years since diagnosis 180 46.1 mean Off EORTC QLQ-C30, HADS MultiD, Domain 6
Vermaete N [47] 2014 Comparator: Cohort Longitudinal Before the start of chemotherapy 12 47 mean Both EORTC QLQ-C30, Distress Barometer MultiD, Domain 5
Kiserud CE [74] 2015 Cohort Cross-sectional Median 16 years since diagnosis 131 46 median Off Fatigue questionnaire, HADS, SF36, Symptom, MultiD 5
Husson O [42] 2015 Comparator: Cohort Cross-sectional Mean 5.3 years since diagnosis 150 46.6 mean Off Fatigue assessment scale Symptom 4
  1. Abbreviations: Tx treatment, MultiD multidimensional, HL Hodgkin’s Lymphoma, RCT randomized controlled trial, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, SF-36/SF-12 Short Form, HUI Health Utilities Index, QOL-CS Quality of Life-Cancer Survivors, CES-D Center for Epidemiologic Studies Depression Scale, GSSI Global Sexual Satisfaction Index, IES Impact of Event Scale, VAS Visual Analogue Scale, CARES-SF Cancer Rehabilitation Evaluation System-Short Form, SDS Symptom Distress Scale, SEIQol-DW Schedule for the Evaluation of the Individual Quality of Life-Direct Weighting, PedsQL Pediatric Quality of Life Inventory, MOS-SSS Medical Outcomes Study-Social Support Survey, FACT-BMT Functional Assessment of Cancer Therapy—Bone Marrow Transplant, FQ Fatigue Questionnaire, MFI Multi-Dimensional Fatigue Inventory, FACIT-Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue, HADS Hospital Anxiety and Depression Scale, BSI Brief Symptom Inventory, POMS Profile of Mood States, PAIS Psychosocial Adjustment to Illness Scale, HDCT high dose chemotherapy, STLI subtotal lymphoid irradiation, CMT combined modality treatment, NS not stated